Business Context and Reporting Period
This Form 8-K Current Report was filed by ImmuCell Corporation on April 4, 2025, with the earliest event reported on the same date. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol ICCC. The filing primarily addresses corporate governance changes and executive appointments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel changes rather than financial performance data.
Material Changes
- Executive Appointment: The Board of Directors elected Timothy C. Fiori to serve as Chief Financial Officer, effective April 7, 2025.
- Background: Mr. Fiori brings 24 years of experience from Idexx Laboratories (Nasdaq: IDXX), most recently serving as Senior Director of Finance, Commercial Operations since 2020.
Guidance, Outlook, and Compensation
While no financial guidance or outlook is provided, the filing details the compensatory arrangements for the new CFO:
- Base Salary: $250,000 annually.
- Benefits: Eligibility for employee benefit plans, including the 2017 Stock Option and Incentive Plan.
- Incentives: An Incentive Compensation Agreement (Exhibit 10.1) provides for cash bonuses tied to specific objectives and outcomes.
Investor Verification Checklist
- Review Exhibit 10.1 (Incentive Compensation Agreement) to understand the specific performance metrics required for Mr. Fiori's cash bonuses.
- Verify the effective start date of April 7, 2025, for the transition of CFO duties.
- Check Exhibit 99.1 for the full press release regarding the appointment.
- Confirm that no other material definitive agreements were entered into simultaneously, as Item 1.01 incorporates Item 5.02 by reference.